In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $534.65, marking a -1.8% move from the previous day.
ISRG's da Vinci 5 wins CE mark, unlocking Europe's surgical robotics market as U.S. adoption shows strong early traction.
The stock market has an incredibly impressive long-term track record of wealth creation, and we can reasonably expect it to continue delivering excellent returns over the next 20 years. Investors can capitalize on this by buying ETFs that track major indexes, or by investing in individual stocks that can perform as well, if not better, than broader equities.
ISRG posted strong Q1 growth, but rising rivals and tighter hospital budgets test its robotics dominance and pricing power.
Key Points in This Article: The robotics industry, projected to grow from $71.2 billion in 2023 to $200 billion by 2030, is driven by AI advancements and demand for automation in logistics and healthcare.
In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $534.38, denoting a +2.44% move from the preceding trading day.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Intuitive Surgical raises 2025 procedure outlook after strong Q1 growth, but rising costs and tariff pressure weigh on margins.
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $515.09, marking a +1.12% move from the previous day.
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Over the past several years, one of the most impressive stocks in the healthcare sector has undeniably been Intuitive Surgical NASDAQ: ISRG. The company's robotics-assisted surgical devices have proven to be extremely innovative, attracting intense demand from doctors around the globe.
Boston Scientific offers steady growth with broader exposure, while Intuitive Surgical leads in robotics but faces margin and tariff headwinds.